Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Key facts

Sponsor

Novartis Pharmaceuticals

Principal Investigator

Novartis Pharmaceuticals

Novartis Pharmaceuticals

Intervention

Iptacopan(drug)

Enrollment

50 enrolled

Eligibility

18-100 years · All sexes

Timeline

2024 – 2029

Study locations (29)

• Novartis Investigative Site, Nanjing, Jiangsu, China
• Novartis Investigative Site, Beijing, China
• Novartis Investigative Site, Shanghai, China
• Novartis Investigative Site, Bordeaux, France
• Novartis Investigative Site, Paris, France
• Novartis Investigative Site, Rouen, France
• Novartis Investigative Site, Toulouse, France
• Novartis Investigative Site, Tours, France
• Novartis Investigative Site, Essen, Germany
• Novartis Investigative Site, Kiel, Germany
• Novartis Investigative Site, Ranica, BG, Italy
• Novartis Investigative Site, Milan, MI, Italy
• Novartis Investigative Site, Roma, RM, Italy
• Novartis Investigative Site, Matsumoto-shi, Nagano, Japan
• Novartis Investigative Site, Iruma-gun, Saitama, Japan
• +14 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Atypical hemolytic uremic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07308574
  Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
  Alexion Pharmaceuticals, Inc.
• RECRUITINGNANCT07218536
  The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
  AstraZeneca
• ACTIVE NOT RECRUITINGNCT06099236
  A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
  AstraZeneca
• ACTIVE NOT RECRUITINGNANCT05985122
  New Analytic Tools for aHUS and C3G Diagnosis
  Mario Negri Institute for Pharmacological Research
• RECRUITINGNANCT05805202
  Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
  Mario Negri Institute for Pharmacological Research
• ACTIVE NOT RECRUITINGPHASE3NCT04958265
  A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
  Hoffmann-La Roche
• ACTIVE NOT RECRUITINGPHASE3NCT04861259
  A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
  Hoffmann-La Roche
• RECRUITINGNCT04745195
  Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
  Maastricht University Medical Center

See all trials for Atypical hemolytic uremic syndrome →